{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:01:25Z","timestamp":1791576085659,"version":"4.3.4"},"reference-count":277,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T00:00:00Z","timestamp":1520640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["150749\/2017-1"],"award-info":[{"award-number":["150749\/2017-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005298","name":"Universidad de Costa Rica","doi-asserted-by":"publisher","award":["OAICE-CAB-05-56-2016"],"award-info":[{"award-number":["OAICE-CAB-05-56-2016"]}],"id":[{"id":"10.13039\/501100005298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006473","name":"Ministerio de Ciencia Tecnolog\u00eda y Telecomunicaciones","doi-asserted-by":"publisher","award":["PEM-066-2015-II"],"award-info":[{"award-number":["PEM-066-2015-II"]}],"id":[{"id":"10.13039\/501100006473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF13OC0005613"],"award-info":[{"award-number":["NNF13OC0005613"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF16OC0019248"],"award-info":[{"award-number":["NNF16OC0019248"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.toxicon.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T01:29:54Z","timestamp":1520731794000},"page":"151-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"special_numbering":"C","title":["Pros and cons of different therapeutic antibody formats for recombinant antivenom development"],"prefix":"10.1016","volume":"146","author":[{"given":"Andreas H.","family":"Laustsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mar\u00eda Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer H.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Berm\u00fadez-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Cerni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas A.","family":"J\u00fcrgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Ledsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Martos-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"\u00d8hlenschl\u00e6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urska","family":"Pus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-6469","authenticated-orcid":false,"given":"Bruno","family":"Lomonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Engmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela B.","family":"Pucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2018.03.004_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/BJ20090697","article-title":"Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom","volume":"424","author":"Abderrazek","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib2","series-title":"Monoclonal Antibodies Approved by the EMA and FDA for Therapeutic Use \u2013 ACTIP","author":"ACTIP","year":"2017"},{"key":"10.1016\/j.toxicon.2018.03.004_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/0974-2700.43190","article-title":"Emergency treatment of a snake bite: pearls from literature","volume":"1","author":"Ahmed","year":"2008","journal-title":"J.\u00a0Emerg. Trauma Shock"},{"key":"10.1016\/j.toxicon.2018.03.004_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0041-0101(03)00170-3","article-title":"Formulation of a liquid ovine Fab-based antivenom for the treatment of envenomation by the Nigerian carpet viper (Echis ocellatus)","volume":"42","author":"Al-Abdulla","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0041-0101(01)00197-0","article-title":"Induction of neutralizing antibodies against Tityus serrulatus scorpion toxins by immunization with a mixture of defined synthetic epitopes","volume":"40","author":"Alvarenga","year":"2002","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.toxicon.2003.09.006","article-title":"Production of monoclonal antibodies capable of neutralizing dermonecrotic activity of Loxosceles intermedia spider venom and their use in a specific immunometric assay","volume":"42","author":"Alvarenga","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.toxicon.2005.07.014","article-title":"Molecular characterization of a neutralizing murine monoclonal antibody against Tityus serrulatus scorpion venom","volume":"46","author":"Alvarenga","year":"2005","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.imlet.2011.05.002","article-title":"Isolation and characterization of a human antibody fragment specific for Ts1 toxin from Tityus serrulatus scorpion","volume":"139","author":"Amaro","year":"2011","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.toxicon.2018.03.004_bib9","unstructured":"Product information. Anavip. [WWW Document], n.d. URL https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM446175.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib10","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain","volume":"286","author":"Andersen","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib11","unstructured":"Antitoxins & Sera: Antiscorpion venom serum [WWW Document], n.d. URL http:\/\/www.vaccinehaffkine.com\/products\/antitoxins-sera\/antiscorpion-venom-serum-detail.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib12","unstructured":"Antivenin (Latrodectus mactans). [WWW Document], n.d. URL http:\/\/www.merck.com\/product\/usa\/pi_circulars\/a\/antivenin\/antivenin_pi.pdf (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib13","unstructured":"Aracmyn Plus - Bioclon | PR Vademecum Mexico [WWW Document], n.d. URL http:\/\/mx.prvademecum.com\/producto.php?producto=8461 (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0041-0101(02)00282-9","article-title":"Protection against dermonecrotic and lethal activities of Loxosceles intermedia spider venom by immunization with a fused recombinant protein","volume":"41","author":"Araujo","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4269\/ajtmh.1999.61.259","article-title":"A\u00a0new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia russelii russelii): a preliminary dose-finding and pharmacokinetic study","volume":"61","author":"Ariaratnam","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.toxicon.2018.03.004_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0035-9203(01)90339-6","article-title":"An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii)","volume":"95","author":"Ariaratnam","year":"2001","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.toxicon.2018.03.004_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s000180300053","article-title":"Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin","volume":"60","author":"Aubrey","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.toxicon.2018.03.004_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.toxicon.2003.11.024","article-title":"Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments","volume":"43","author":"Aubrey","year":"2004","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4049\/jimmunol.141.1.214","article-title":"Monoclonal antibodies to scorpion toxins. Characterization and molecular mechanisms of neutralization","volume":"141","author":"Bahraoui","year":"1988","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib20","unstructured":"Product information. Banded Krait Antivenin. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_thailand-thairedcross-bandedkrait_2011-07-04.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1020917122093","article-title":"Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis","volume":"27","author":"Bauer","year":"1999","journal-title":"J.\u00a0Pharmacokinet. Biopharm."},{"key":"10.1016\/j.toxicon.2018.03.004_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/jir.2010.0086","article-title":"On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis","volume":"30","author":"van Beers","year":"2010","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chroma.2016.02.068","article-title":"Affitins as robust tailored reagents for affinity chromatography purification of antibodies and non-immunoglobulin proteins","volume":"1441","author":"B\u00e9har","year":"2016","journal-title":"J.\u00a0Chromatogr. A"},{"key":"10.1016\/j.toxicon.2018.03.004_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10295-013-1235-0","article-title":"Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells","volume":"40","author":"Berlec","year":"2013","journal-title":"J.\u00a0Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib25","doi-asserted-by":"crossref","first-page":"e3039","DOI":"10.1371\/journal.pntd.0003039","article-title":"Viper and cobra venom neutralization by alginate coated multicomponent polyvalent antivenom administered by the oral route","volume":"8","author":"Bhattacharya","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib26","unstructured":"Biol\u00f3gicos, P., Cayatopa, Q.J.J.C., Rosales, Q.G.M., Yanavilca, Q.R.A.M., Paz, Q.M.C., Paredes, Q.F.F., Gutarra, B.M.R., n.d. VADEM\u00c9CUM 2005."},{"key":"10.1016\/j.toxicon.2018.03.004_bib27","unstructured":"Product information. Black Snake Antivenom. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_australia-csl-blacksnake_2011-07-28.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib28","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1021\/bc100261d","article-title":"Effects of charge on antibody tissue distribution and pharmacokinetics","volume":"21","author":"Boswell","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib29","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1021\/bi00541a016","article-title":"Neutralizing monoclonal antibody specific for Naja nigricollis toxin alpha: preparation, characterization, and localization of the antigenic binding site","volume":"21","author":"Boulain","year":"1982","journal-title":"Biochem. (Mosc.)"},{"key":"10.1016\/j.toxicon.2018.03.004_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymeth.2013.06.010","article-title":"Mammalian cell display for the discovery and optimization of antibody therapeutics","volume":"65","author":"Bowers","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.toxicon.2018.03.004_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.toxicon.2013.07.018","article-title":"Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms","volume":"74","author":"Boyer","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2031352a0","article-title":"A\u00a0theoretical model of gamma-globulin catabolism","volume":"203","author":"Brambell","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.toxicon.2018.03.004_bib33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.toxicon.2010.02.012","article-title":"Antivenom: the most cost-effective treatment in the world?","volume":"55","author":"Brown","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib34","unstructured":"Product information. Brown Snake Antivenom. [WWW Document], n.d. URL http:\/\/www.seqirus.com.au\/docs\/456\/953\/Brown%20Snake%20Antivenom%20-%20Approved%20Product%20Information_V6_2june2017.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/B978-0-444-53490-3.00028-5","article-title":"Neurological effects of venomous bites and stings: snakes, spiders, and scorpions","volume":"114","author":"Del Brutto","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/15563650.2016.1277235","article-title":"Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation","volume":"55","author":"Brvar","year":"2017","journal-title":"Clin. Toxicol. Phila. Pa"},{"key":"10.1016\/j.toxicon.2018.03.004_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.toxicon.2007.11.014","article-title":"Monoclonal antibody fragment from combinatorial phage display library neutralizes alpha-latrotoxin activity and abolishes black widow spider venom lethality, in mice","volume":"51","author":"Bugli","year":"2008","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib38","first-page":"120","article-title":"L\u2019immunisation artificielle des animaux contre le venin des serpents, et la th\u00e9rapeutic exp\u00e9rimentale des morsures venimeuses","volume":"46","author":"Calmette","year":"1894","journal-title":"Comptes Rendus Soci\u00e9t\u00e9 Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/BCJ20160577","article-title":"Venomics: integrative venom proteomics and beyond","volume":"474","author":"Calvete","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.annemergmed.2007.09.036","article-title":"Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom","volume":"51","author":"Cannon","year":"2008","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-3083.2000.00709.x","article-title":"Neutralizing human anti crotoxin scFv isolated from a nonimmunized phage library","volume":"51","author":"Cardoso","year":"2000","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib42","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1371\/journal.pntd.0000851","article-title":"Pre-clinical assays predict Pan-African Echis viper efficacy for a species-specific antivenom","volume":"4","author":"Casewell","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.toxicon.2014.05.017","article-title":"A\u00a0neutralizing recombinant single chain antibody, scFv, against BaP1, A P-I hemorrhagic metalloproteinase from Bothrops asper snake venom","volume":"87","author":"Castro","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0958-1669(00)00198-1","article-title":"Therapeutic antibody expression technology","volume":"12","author":"Chadd","year":"2001","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.taap.2005.05.015","article-title":"Brown spider dermonecrotic toxin directly induces nephrotoxicity","volume":"211","author":"Chaim","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib46","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/11717","article-title":"Therapeutic antibody fragments with prolonged in\u00a0vivo half-lives","volume":"17","author":"Chapman","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmr.300030204","article-title":"Recognition of the acetylcholine receptor binding site of a long-chain neurotoxin by toxin-specific monoclonal antibodies","volume":"3","author":"Charpentier","year":"1990","journal-title":"J.\u00a0Mol. Recognit."},{"key":"10.1016\/j.toxicon.2018.03.004_bib48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/toxins4070554","article-title":"Humanized-single domain antibodies (VH\/VHH) that bound specifically to Naja kaouthia phospholipase A2 and neutralized the enzymatic activity","volume":"4","author":"Chavanayarn","year":"2012","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2018.03.004_bib49","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1021\/bc200624a","article-title":"Glycoengineering approach to half-life extension of recombinant biotherapeutics","volume":"23","author":"Chen","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.actatropica.2008.05.021","article-title":"Epidemiology of scorpionism: a global appraisal","volume":"107","author":"Chippaux","year":"2008","journal-title":"Acta Trop."},{"key":"10.1016\/j.toxicon.2018.03.004_bib51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0014-5793(99)01179-5","article-title":"Monoclonal antibodies against the Androctonus australis hector scorpion neurotoxin I: characterisation and use for venom neutralisation","volume":"458","author":"Clot-Faybesse","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.toxicon.2018.03.004_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1021\/bc700319r","article-title":"Modulation of antibody pharmacokinetics by chemical polysialylation","volume":"19","author":"Constantinou","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097438","article-title":"Potent and specific inhibition of glycosidases by small artificial binding proteins (Affitins)","volume":"9","author":"Correa","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.toxicon.2018.03.004_bib54","unstructured":"Crofab (Crotalidae Polyvalent Immune Fab Ovine): Side Effects, Interactions, Warning, Dosage & Uses [WWW Document], n.d.. RxList. URL https:\/\/www.rxlist.com\/crofab-drug.htm (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00007890-198702000-00031","article-title":"Acute serum sickness with glomerulonephritis induced by antithymocyte globulin","volume":"43","author":"Cunningham","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.toxicon.2018.03.004_bib56","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/toxins6051526","article-title":"Ophiophagus hannah venom: proteome, components bound by N.\u00a0kaouthia antivenin and neutralization by N.\u00a0kaouthia neurotoxin-specific human scFv","author":"Danpaiboon","year":"2014","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2018.03.004_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1067\/mem.2001.113372","article-title":"Efficacy, safety, and use of snake antivenoms in the United States","volume":"37","author":"Dart","year":"2001","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib59","unstructured":"Product information. Death Adder Antivenom. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_australia-csl-deathadder_2011-07-28.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/17425255.2012.643868","article-title":"Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?","volume":"8","author":"Deng","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/mabs.1.2.7909","article-title":"Immunotoxicity of monoclonal antibodies","volume":"1","author":"Descotes","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.toxicon.2018.03.004_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0300-483X(00)00400-5","article-title":"Gell and Coombs's classification: is it still valid?","volume":"158","author":"Descotes","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.toxicon.2018.03.004_bib63","unstructured":"Detalle del Producto. Suero antiloxosc\u00e9lico monovalente. [WWW Document], n.d. URL http:\/\/www.ins.gob.pe\/insvirtual\/hdetprod.aspx?1596 (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib64","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1432-1327.2001.01923.x","article-title":"Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector","volume":"268","author":"Devaux","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib65","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1432-1327.2001.01923.x","article-title":"Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin Aahl from the venom of the scorpion Androctonus australis hector","volume":"268","author":"Devaux","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib66","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.vaccine.2014.02.012","article-title":"Generation and molecular characterization of a monoclonal antibody reactive with conserved epitope in sphingomyelinases D from Loxosceles spider venoms","volume":"32","author":"Dias-Lopes","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.toxicon.2018.03.004_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.toxicon.2018.03.004_bib68","doi-asserted-by":"crossref","first-page":"36629","DOI":"10.1038\/srep36629","article-title":"High-throughput immuno-profiling of mamba (Dendroaspis) venom toxin epitopes using high-density peptide microarrays","volume":"6","author":"Engmark","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxicon.2018.03.004_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxicon.2017.08.028","article-title":"High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction","volume":"138","author":"Engmark","year":"2017","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib70","doi-asserted-by":"crossref","first-page":"e0005768","DOI":"10.1371\/journal.pntd.0005768","article-title":"Cross-recognition of a pit viper (Crotalinae) polyspecific antivenom explored through high-density peptide microarray epitope mapping","volume":"11","author":"Engmark","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib71","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0300-9084(00)01166-4","article-title":"Structure and pharmacology of spider venom neurotoxins","volume":"82","author":"Escoubas","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.toxicon.2018.03.004_bib72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pep.2010.05.009","article-title":"The production, characterisation and enhanced pharmacokinetics of scFv\u2013albumin fusions expressed in Saccharomyces cerevisiae","volume":"73","author":"Evans","year":"2010","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.toxicon.2018.03.004_bib73","first-page":"93","article-title":"Pharmacokinetics. Biochem. Pharmacol","volume":"87","author":"Fan","year":"2014","journal-title":"Special Issue Pharmacol. 21st Century Biomed. Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib74","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/0009922812441660","article-title":"The use and tolerability of Crotalidae Polyvalent Immune FAB (Ovine) in pediatric envenomations","volume":"51","author":"Farrar","year":"2012","journal-title":"Clin. Pediatr. (Phila.)"},{"key":"10.1016\/j.toxicon.2018.03.004_bib75","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.toxicon.2010.07.014","article-title":"Immunochemical and biological characterization of monoclonal antibodies against BaP1, a metalloproteinase from Bothrops asper snake venom","volume":"56","author":"Fernandes","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib76","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmb.2011.06.031","article-title":"Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics","volume":"411","author":"Finch","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.toxicon.2013.05.005","article-title":"Bothropic antivenom based on monoclonal antibodies, is it possible?","volume":"71","author":"Frauches","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib78","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2013.00217","article-title":"Expression of recombinant antibodies","volume":"4","author":"Frenzel","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib79","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1742-7843.2011.00821.x","article-title":"Production of human antibody fragments binding to melittin and phospholipase A2 in Africanised bee venom: minimising venom toxicity","volume":"110","author":"Funayama","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib80","unstructured":"Funnel Web Spider Antivenom - Current Cunsumer Medicine Information Jan 2017. [WWW Document], n.d. URL http:\/\/www.csl.com.au\/docs\/266\/458\/Funnel%20Web%20Spider%20Antivenom%20-%20Current%20Cunsumer%20Medicine%20Information_Jan%202017.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12934-016-0419-5","article-title":"Systematic screening of soluble expression of antibody fragments in the cytoplasm of E.\u00a0coli","volume":"15","author":"Gaciarz","year":"2016","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.toxicon.2018.03.004_bib82","article-title":"Snake venom cytotoxins, phospholipase A2s, and Zn2+-dependent metalloproteinases: mechanisms of action and pharmacological relevance","volume":"4","author":"Gasanov","year":"2014","journal-title":"J.\u00a0Clin. Toxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib83","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0022-2836(86)90503-6","article-title":"Preliminary crystallographic study of the Fab fragment of a monoclonal antibody directed against a cobra cardiotoxin","volume":"189","author":"Guillon","year":"1986","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib84","first-page":"676","article-title":"Improving antivenom availability and accessibility: science, technology, and beyond. Toxicon","volume":"60","author":"Guti\u00e9rrez","year":"2012"},{"key":"10.1016\/j.toxicon.2018.03.004_bib85","series-title":"Animal Toxins: State of the Art. Perspectives in Health and Biotechnology","article-title":"Snake antivenoms","author":"Guti\u00e9rrez","year":"2009"},{"key":"10.1016\/j.toxicon.2018.03.004_bib86","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00003088-200342080-00002","article-title":"Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation","volume":"42","author":"Guti\u00e9rrez","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxicon.2018.03.004_bib87","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1371\/journal.pmed.0030150","article-title":"Confronting the neglected problem of snake bite envenoming: the need for a global partnership","volume":"3","author":"Guti\u00e9rrez","year":"2006","journal-title":"PLOS Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib88","doi-asserted-by":"crossref","first-page":"17063","DOI":"10.1038\/nrdp.2017.63","article-title":"Snakebite envenoming","volume":"3","author":"Guti\u00e9rrez","year":"2017","journal-title":"Nat. Rev. Dis. Primer"},{"key":"10.1016\/j.toxicon.2018.03.004_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9050163","article-title":"Preclinical evaluation of the efficacy of antivenoms for snakebite envenoming: state-of-the-art and challenges ahead","volume":"9","author":"Guti\u00e9rrez","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2018.03.004_bib90","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.toxicon.2018.03.004_bib91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib92","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.vaccine.2003.09.046","article-title":"Development of venom toxin-specific antibodies by DNA immunisation: rationale and strategies to improve therapy of viper envenoming","volume":"22","author":"Harrison","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.toxicon.2018.03.004_bib93","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jprot.2011.06.019","article-title":"Research strategies to improve snakebite treatment: challenges and progress","volume":"74","author":"Harrison","year":"2011","journal-title":"J.\u00a0Proteomics."},{"key":"10.1016\/j.toxicon.2018.03.004_bib94","doi-asserted-by":"crossref","first-page":"e0005969","DOI":"10.1371\/journal.pntd.0005969","article-title":"Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa","volume":"11","author":"Harrison","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib95","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0041-0101(92)90851-U","article-title":"Pioneers of anti-venomous serotherapy: Dr vital Brazil (1865-1950)","volume":"30","author":"Hawgood","year":"1992","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib96","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1099\/0022-1317-80-6-1529","article-title":"In\u00a0vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus Carrier chimpanzee","volume":"80","author":"Heijtink","year":"1999","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.toxicon.2014.07.015","article-title":"Freeze-dried snake antivenoms formulated with sorbitol, sucrose or mannitol: comparison of their stability in an accelerated test","volume":"90","author":"Herrera","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib98","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.toxicon.2017.05.006","article-title":"Freeze-dried EchiTAb+ICP antivenom formulated with sucrose is more resistant to thermal stress than the liquid formulation stabilized with sorbitol","volume":"133","author":"Herrera","year":"2017","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib99","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1016\/j.molimm.2008.04.011","article-title":"VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'","volume":"45","author":"Hmila","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib100","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1096\/fj.09-148213","article-title":"A\u00a0bispecific nanobody to provide full protection against lethal scorpion envenoming","volume":"24","author":"Hmila","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib101","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.taap.2012.07.033","article-title":"Pre-clinical studies of toxin-specific Nanobodies: evidence of in\u00a0vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming","volume":"264","author":"Hmila","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib102","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-1-59745-554-1_18","article-title":"Mammalian cell display for antibody engineering","volume":"525","author":"Ho","year":"2009","journal-title":"Methods Mol. Biol. Clifton N. J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib103","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4269\/ajtmh.1990.42.260","article-title":"Pharmacokinetics of three commercial antivenoms in patients envenomed by the malayan pit viper, Calloselasma rhodostoma, in Thailand","volume":"42","author":"Ho","year":"1990","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.toxicon.2018.03.004_bib104","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1074\/jbc.M111.311522","article-title":"Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains","volume":"287","author":"Hutt","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0041-0101(88)90169-9","article-title":"Characterisation of a monoclonal antibody capable of neutralising the haemorrhagic activity of West African Echis carinatus (carpet viper) venom","volume":"26","author":"Iddon","year":"1988","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib106","unstructured":"Instituto Vital Brazil - Soro Antilatrod\u00e9ctico. [WWW Document], n.d. URL http:\/\/www.ivb.rj.gov.br\/soros_produzidos.html (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib107","unstructured":"Instructions for use. Alacramyn\u00ae. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_mexico-bioclon-alacramyn_2011-07-28.pdf (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib108","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5694\/j.1326-5377.2008.tb01721.x","article-title":"Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis","volume":"188","author":"Isbister","year":"2008","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.toxicon.2018.03.004_bib109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2125.2007.03004.x","article-title":"A\u00a0comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom","volume":"65","author":"Isbister","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib110","doi-asserted-by":"crossref","first-page":"e0003873","DOI":"10.1371\/journal.pntd.0003873","article-title":"Population pharmacokinetics of an indian F(ab\u2019)2 snake antivenom in patients with Russell's viper (Daboia russelii) bites","volume":"9","author":"Isbister","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib111","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0041-0101(96)83665-8","article-title":"Serotherapy of scorpion envenoming: pharmacokinetics of antivenoms and a critical assessment of their usefulness","volume":"2","author":"Ismail","year":"1996","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib112","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0041-0101(97)00062-7","article-title":"Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its specific antivenins: flash absorption and distribution of the venom and its toxin versus slow absorption and distribution of IgG, F(ab')2 and F(ab) of the antivenin","volume":"36","author":"Ismail","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib113","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1472-6750-13-52","article-title":"High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells","volume":"13","author":"J\u00e4ger","year":"2013","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib114","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0041-0101(99)00175-0","article-title":"Characterization of four distinct monoclonal antibodies specific to BmK AS-1, a novel scorpion bioactive polypeptide","volume":"38","author":"Jia","year":"2000","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib115","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jmb.2004.12.060","article-title":"Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2","volume":"346","author":"Ju\u00e1rez-Gonz\u00e1lez","year":"2005","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib116","article-title":"A\u00a0synthetic biology approach for consistent production of plant-made recombinant polyclonal antibodies against snake venom toxins","author":"Julve Parre\u00f1o","year":"2017","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib117","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02786322","article-title":"Finally! the Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG","volume":"16","author":"Junghans","year":"1997","journal-title":"Immunol. Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib118","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00018-006-6401-3","article-title":"Using a recombinant bispecific antibody to block Na+-channel toxins protects against experimental scorpion envenoming","volume":"64","author":"Juste","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.toxicon.2018.03.004_bib119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","article-title":"Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies","volume":"21\u201322","author":"Kamath","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.toxicon.2018.03.004_bib121","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.toxicon.2010.07.010","article-title":"Structure, function and evolution of three-finger toxins: mini proteins with multiple targets","volume":"56","author":"Kini","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib122","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-1759(96)00188-3","article-title":"High level production of soluble single chain antibodies in small-scale Escherichia coli cultures","volume":"200","author":"Kipriyanov","year":"1997","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.toxicon.2018.03.004_bib123","first-page":"422","article-title":"The pharmacokinetic characteristics of glycolated humanized anti-tac Fabs are determined by their isoelectric points","volume":"59","author":"Kobayashi","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib124","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jprot.2008.12.007","article-title":"Human monoclonal scFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin","volume":"72","author":"Kulkeaw","year":"2009","journal-title":"J.\u00a0Proteomics"},{"key":"10.1016\/j.toxicon.2018.03.004_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8080244","article-title":"A\u00a0single dose of viperfavTM may Be inadequate for Vipera ammodytes snake bite: a case report and pharmacokinetic evaluation","volume":"8","author":"Kurtovi\u0107","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2018.03.004_bib127","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1380-2933(97)00068-7","article-title":"Biologically active human anti-crotoxin scFv isolated from a semi-synthetic phage library","volume":"3","author":"Lafaye","year":"1997","journal-title":"Immunotechnology Int. J. Immunol. Eng."},{"key":"10.1016\/j.toxicon.2018.03.004_bib128","article-title":"Mini review: recombinant production of tailored bio-pharmaceuticals in different Bacillus strains and future perspectives","author":"Lakowitz","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.toxicon.2018.03.004_bib129","doi-asserted-by":"crossref","unstructured":"Laustsen, A.H., n.d. Guiding recombinant antivenom development by omics technologies. New Biotechnol. in press. https:\/\/doi.org\/10.1016\/j.nbt.2017.05.005.","DOI":"10.1016\/j.nbt.2017.05.005"},{"key":"10.1016\/j.toxicon.2018.03.004_bib130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15569543.2016.1220397","article-title":"Toxin synergism in snake venoms","volume":"35","author":"Laustsen","year":"2016","journal-title":"Toxin Rev."},{"key":"10.1016\/j.toxicon.2018.03.004_bib131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.toxicon.2015.07.334","article-title":"Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score","volume":"104","author":"Laustsen","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib132","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.2174\/1381612822666160623073438","article-title":"From fangs to pharmacology: the future of snakebite envenoming therapy","volume":"22","author":"Laustsen","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.toxicon.2018.03.004_bib133","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/538041e","article-title":"Snakebites: costing recombinant antivenoms","volume":"538","author":"Laustsen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.toxicon.2018.03.004_bib134","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/toxins8080226","article-title":"Biotechnological trends in spider and scorpion antivenom development","volume":"8","author":"Laustsen","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2018.03.004_bib135","doi-asserted-by":"crossref","first-page":"e0005361","DOI":"10.1371\/journal.pntd.0005361","article-title":"Recombinant snakebite antivenoms: a cost-competitive solution to a neglected tropical disease?","volume":"11","author":"Laustsen","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib136","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.annemergmed.2012.08.027","article-title":"Failure to develop sensitization despite repeated administration of ovine fab snake antivenom: update of a single-patient, multicenter case series","volume":"61","author":"Lavonas","year":"2013","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/AEM.02608-15","article-title":"Antibodies against venom of the snake Deinagkistrodon acutus","volume":"82","author":"Lee","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib138","first-page":"1627","article-title":"Immunoglobulin G and F(ab\u2019)2 polyvalent antivenoms do not differ in their ability to neutralize hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon","volume":"35","author":"Le\u00f3n","year":"1997"},{"key":"10.1016\/j.toxicon.2018.03.004_bib139","first-page":"233","article-title":"Comparative study on the ability of IgG and Fab sheep antivenoms to neutralize local hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon","volume":"38","author":"Le\u00f3n","year":"2000"},{"key":"10.1016\/j.toxicon.2018.03.004_bib140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0041-0101(00)00209-9","article-title":"Comparison between IgG and F(ab')2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions","volume":"39","author":"Le\u00f3n","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib141","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxicon.2013.09.010","article-title":"Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms","volume":"76","author":"Le\u00f3n","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib142","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0041-0101(93)90134-5","article-title":"Cross-reactivities of monoclonal antibodies to a myotoxin from the venom of the broad-banded copperhead (Agkistrodon contortrix laticinctus)","volume":"31","author":"Li","year":"1993","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib143","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0041-0101(96)00043-8","article-title":"Fab fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole soluble venom from the scorpion Centruroides noxius Hoffmann","volume":"34","author":"Licea","year":"1996","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib144","first-page":"1","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.toxicon.2018.03.004_bib145","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.toxicon.2018.03.004_bib146","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0041-0101(88)90249-8","article-title":"Production and partial characterization of monoclonal antibodies to Bothrops asper (terciopelo) myotoxin","volume":"26","author":"Lomonte","year":"1988","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib147","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0041-0101(92)90866-4","article-title":"Neutralization of myotoxic phospholipases A2 from the venom of the snake Bothrops asper by monoclonal antibodies","volume":"30","author":"Lomonte","year":"1992","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib148","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1580\/1080-6032(2003)14[220:SSFAOA]2.0.CO;2","article-title":"Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation","volume":"14","author":"LoVecchio","year":"2003","journal-title":"Wilderness Environ. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib149","series-title":"Advances in Protein Chemistry and Structural Biology","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-386483-3.00004-5","article-title":"Aggregation, stability, and formulation of human antibody therapeutics","author":"Lowe","year":"2011"},{"key":"10.1016\/j.toxicon.2018.03.004_bib150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12934-015-0241-5","article-title":"Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins","volume":"14","author":"Mamat","year":"2015","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.toxicon.2018.03.004_bib151","first-page":"155","article-title":"Production and characterization of monoclonal antibodies neutralizing the postsynaptic neurotoxin 3","volume":"3","author":"Masathien","year":"1994","journal-title":"J.\u00a0Nat. Toxins"},{"key":"10.1016\/j.toxicon.2018.03.004_bib152","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0041-0101(88)90005-0","article-title":"Kinetics of envenomation with Russell's viper (Vipera russelli) venom and of antivenom use in mice","volume":"26","author":"Maung-Maung-Thwin","year":"1988","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib153","unstructured":"MAVIN Poison Centre Munich - Scorpifav. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/productinfo\/SCORPIFAV.html (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib154","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.300.1.346","article-title":"Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the Disappearance of target antigen","volume":"300","author":"Meijer","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.toxicon.2018.03.004_bib155","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(95)02095-0","article-title":"Specificity and binding affinity of an anti-crotoxin combinatorial antibody selected from a phage-displayed library","volume":"50","author":"Meng","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib156","doi-asserted-by":"crossref","first-page":"23775","DOI":"10.1074\/jbc.272.38.23775","article-title":"The functional architecture of an acetylcholine receptor-mimicking antibody","volume":"272","author":"M\u00e9rienne","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib157","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4269\/ajtmh.1997.56.291","article-title":"First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom","volume":"56","author":"Meyer","year":"1997","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.toxicon.2018.03.004_bib158","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.27854","article-title":"Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody","volume":"6","author":"Monnet","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.toxicon.2018.03.004_bib159","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.toxicon.2007.10.009","article-title":"Neutralization of hemorrhagic snake venom metalloproteinase HR1a from Protobothrops flavoviridis by human monoclonal antibody","volume":"51","author":"Morine","year":"2008","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of monoclonal antibodies","volume":"24","author":"Mould","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.toxicon.2018.03.004_bib161","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-5793(98)01647-0","article-title":"A\u00a0recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector","volume":"442","author":"Mousli","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.toxicon.2018.03.004_bib162","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M700820200","article-title":"Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin","volume":"282","author":"M\u00fcller","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib163","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib164","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1742-7843.2008.00322.x","article-title":"Expression of human recombinant antibody fragments capable of partially inhibiting the phospholypase activity of Crotalus durissus terrificus venom","volume":"105","author":"Oliveira","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol"},{"key":"10.1016\/j.toxicon.2018.03.004_bib166","unstructured":"Our Products - Reclusmyn. [WWW Document], n.d. URL http:\/\/www.bioclon.com.mx\/bioclon\/html\/reclusmyn_en.html (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib167","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/protein\/gzu042","article-title":"Affinity transfer to the archaeal extremophilic Sac7d protein by insertion of a CDR","volume":"27","author":"Pacheco","year":"2014","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"10.1016\/j.toxicon.2018.03.004_bib168","unstructured":"Package leaflet: Soro antiarachnidico - Butantan. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_brasil-butantan-antiarachnidico_2011-07-28.pdf (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib169","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1023\/A:1016279219619","article-title":"Snake F(ab\u2019)2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits","volume":"12","author":"P\u00e9pin-Covatta","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib170","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0041-008X(96)80033-0","article-title":"Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab\u2019)2-scorpion venom interactions","volume":"141","author":"P\u00e9pin-Covatta","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib171","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0041-0101(84)90188-0","article-title":"Production of a monoclonal antibody against hemorrhagic activity of Crotalus atrox (western diamondback rattlesnake) venom","volume":"22","author":"Perez","year":"1984","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib172","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.toxicon.2016.01.062","article-title":"Human scFv antibodies (Afribumabs) against Africanized bee venom: advances in melittin recognition","volume":"112","author":"Pessenda","year":"2016","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib173","first-page":"111","article-title":"Sur la propri\u00e9t\u00e9 antitoxique du sang des animaux vaccin\u00e9s contre le venin de vip\u00e8re","volume":"46","author":"Phisalix","year":"1894","journal-title":"Comptes Rendus Soci\u00e9t\u00e9 Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib174","unstructured":"Polyvalent Scorpion Antivenom | National Antivenom and Vaccine Production Center. [WWW Document], n.d. URL http:\/\/www.antivenom-center.com\/navpc-products\/polyvalent-scorpion-antivenom\/(accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib175","unstructured":"Product information. Polyvalent Snake Antivenom. [WWW Document], n.d. URL http:\/\/www.csl.com.au\/docs\/454\/836\/Polyvalent%20Snake%20Antivenom%20-%20current%20Cunsumer%20Medicine%20Information%20Oct%202016.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib176","unstructured":"Product information. Soro Antibotropico pentavalente. [WWW Document], n.d. URL http:\/\/www.butantan.gov.br\/Documents\/soro-antibotr%C3%B3pico-pentavalente.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib177","first-page":"31","article-title":"Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals","volume":"47","author":"Pucca","year":"2011","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.toxicon.2018.03.004_bib178","first-page":"18","article-title":"Monoclonal antibody (scfv) against the venom of the scorpion Tityus serrulatus, produced by phage display technique, is capable to recognize and inhibit the action of the ts1 toxin","volume":"1","author":"Pucca","year":"2011","journal-title":"Epeq\/Fafibe"},{"key":"10.1016\/j.toxicon.2018.03.004_bib179","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/1547691X.2011.649220","article-title":"Serrumab: a human monoclonal antibody that counters the biochemical and immunological effects of Tityus serrulatus venom","volume":"9","author":"Pucca","year":"2012","journal-title":"J.\u00a0Immunotoxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/1547691X.2013.809175","article-title":"Serrumab: a novel human single chain-fragment antibody with multiple scorpion toxin-neutralizing capacities","volume":"11","author":"Pucca","year":"2014","journal-title":"J.\u00a0Immunotoxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib181","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1021\/bi00045a005","article-title":"Analysis of the pH dependence of the neonatal Fc receptor\/immunoglobulin G interaction using antibody and receptor variants","volume":"34","author":"Raghavan","year":"1995","journal-title":"Biochem. (Mosc.)"},{"key":"10.1016\/j.toxicon.2018.03.004_bib182","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0168-1656(85)90028-8","article-title":"Large-scale cultivation of hybridoma cells","volume":"2","author":"Randerson","year":"1985","journal-title":"J.\u00a0Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib183","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib184","article-title":"DARPins bioengineering and its theranostic approaches: emerging trends in protein engineering","author":"Rasool","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.toxicon.2018.03.004_bib185","unstructured":"Red Back Spider Antivenom - Current Consumer Medicine Information Febr 2017. [WWW Document], n.d. URL http:\/\/www.csl.com.au\/docs\/441\/447\/Red%20Back%20Spider%20Antivenom%20-%20Current%20Consumer%20Medicine%20Information%20Febr%202017.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib186","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s12010-014-1207-5","article-title":"Formulation and characterisation of antibody-conjugated soy protein nanoparticles \u2014 implications for neutralisation of snake venom with improved efficiency","volume":"174","author":"Renu","year":"2014","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib187","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/j.1742-4658.2005.04687.x","article-title":"A\u00a0strategy for the generation of specific human antibodies by directed evolution and phage display","volume":"272","author":"Ria\u00f1o-Umbarila","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib188","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1074\/jbc.M110.189175","article-title":"Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment","volume":"286","author":"Ria\u00f1o-Umbarila","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib189","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.toxicon.2013.09.016","article-title":"A\u00a0novel human recombinant antibody fragment capable of neutralizing Mexican scorpion toxins","volume":"76","author":"Ria\u00f1o-Umbarila","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib190","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1074\/jbc.M115.685297","article-title":"Optimal neutralization of Centruroides noxius venom is understood through a structural complex between two antibody fragments and the Cn2 toxin","volume":"291","author":"Ria\u00f1o-Umbarila","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib191","doi-asserted-by":"crossref","first-page":"e69495","DOI":"10.1371\/journal.pone.0069495","article-title":"In\u00a0vivo neutralization of \u03b1-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-fc antibody","volume":"8","author":"Richard","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.toxicon.2018.03.004_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)36597-8","article-title":"Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy","volume":"281","author":"Rivi\u00e8re","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.toxicon.2018.03.004_bib193","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1182\/blood-2012-06-438804","article-title":"Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia","volume":"120","author":"Robak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.toxicon.2018.03.004_bib194","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0041-0101(97)00015-9","article-title":"Purification and stability studies of immunoglobulins from Lachesis muta muta antivenom","volume":"35","author":"Rodrigues-Silva","year":"1997","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0041-0101(97)00101-3","article-title":"Thermal stability studies of hyperimmune horse antivenoms","volume":"37","author":"Rodrigues-Silva","year":"1999","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib196","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jmb.2012.07.007","article-title":"A\u00a0single mutation in framework 2 of the heavy variable domain improves the properties of a diabody and a related single-chain antibody","volume":"423","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib197","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.toxicon.2016.05.011","article-title":"Broadening the neutralizing capacity of a family of antibody fragments against different toxins from Mexican scorpions","volume":"119","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2016","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib198","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/1547691X.2012.703253","article-title":"Human antibody fragments specific for Bothrops jararacussu venom reduce the toxicity of other Bothrops sp. venoms","volume":"10","author":"Roncolato","year":"2013","journal-title":"J.\u00a0Immunotoxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib199","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.toxicon.2014.11.001","article-title":"Phage display as a novel promising antivenom therapy: a review","volume":"93","author":"Roncolato","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib200","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib201","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/cbr.2009.0627","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"Rudnick","year":"2009","journal-title":"Cancer biother. Radiopharm."},{"key":"10.1016\/j.toxicon.2018.03.004_bib202","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079971","article-title":"Production of the first effective hyperimmune equine serum antivenom against africanized bees","volume":"8","author":"Santos","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.toxicon.2018.03.004_bib203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1553-2712.2011.01276.x","article-title":"Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis","volume":"19","author":"Schaeffer","year":"2012","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/15563659409011037","article-title":"Antibody treatment of toxin poisoning recent advances","volume":"32","author":"Scherrmann","year":"1994","journal-title":"J.\u00a0Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib205","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1021\/ar5003973","article-title":"The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds","volume":"48","author":"Schiefner","year":"2015","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib206","doi-asserted-by":"crossref","first-page":"e2826","DOI":"10.1371\/journal.pntd.0002826","article-title":"Use of a synthetic biosensor for neutralizing activity-biased selection of monoclonal antibodies against atroxlysin-I, an hemorrhagic metalloproteinase from Bothrops atrox snake venom","volume":"8","author":"Schneider","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib207","unstructured":"Scorpion Anti Serum | VINS BioProducts Limited, n.d."},{"key":"10.1016\/j.toxicon.2018.03.004_bib208","unstructured":"Premium Serums. Scorpion Venom Antiserum (India). [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product8.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib209","unstructured":"Premium Serums. Scorpion Venom Antiserum (North Africa). [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product9.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib210","unstructured":"Sea Snake Antivenom - Current Consumer Medicine information. [WWW Document], n.d. URL http:\/\/www.csl.com.au\/docs\/882\/499\/Sea%20Snake%20Antivenom%20-%20Current%20Consumer%20Medicine%20information_Nov%202017.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib211","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.toxicon.2009.01.012","article-title":"Stability of equine IgG antivenoms obtained by caprylic acid precipitation: towards a liquid formulation stable at tropical room temperature","volume":"53","author":"Segura","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib212","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.toxicon.2010.07.001","article-title":"Preclinical assessment of the neutralizing capacity of antivenoms produced in six Latin American countries against medically-relevant Bothrops snake venoms","volume":"56","author":"Segura","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib213","first-page":"93","article-title":"Assessment of snake antivenom purity by comparing physicochemical and immunochemical methods","volume":"41","author":"Segura","year":"2013","journal-title":"Biol. J. Int. Assoc. Biol. Stand"},{"key":"10.1016\/j.toxicon.2018.03.004_bib214","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mem.2001.113135","article-title":"Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies","volume":"37","author":"Seifert","year":"2001","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.toxicon.2003.10.015","article-title":"Bacterial expression, purification and functional characterization of a recombinant chimeric Fab derived from murine mAb BCF2 that neutralizes the venom of the scorpion Centruroides noxius Hoffmann","volume":"43","author":"Selisko","year":"2004","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib216","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.toxicon.2004.07.032","article-title":"Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')2 extrusion mechanism from blood to tissues","volume":"44","author":"Sevcik","year":"2004","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib217","doi-asserted-by":"crossref","first-page":"e1000435","DOI":"10.1371\/journal.pmed.1000435","article-title":"Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial","volume":"8","author":"de Silva","year":"2011","journal-title":"PLoS Med."},{"key":"10.1016\/j.toxicon.2018.03.004_bib218","article-title":"In\u00a0vitro-engineered non-antibody protein therapeutics","author":"Simeon","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.toxicon.2018.03.004_bib219","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a versatile platform for drug half-life extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Biochim. Biophys. Acta BBA - Gen. Subj. Serum Albumin"},{"key":"10.1016\/j.toxicon.2018.03.004_bib220","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1128\/AEM.70.12.7033-7039.2004","article-title":"Broad-host-range plasmid pJB658 can be used for industrial-level production of a secreted host-toxic single-chain antibody fragment in Escherichia coli","volume":"70","author":"Sletta","year":"2004","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib221","unstructured":"Product information. Snake Venom Antiserum I.P. [WWW Document], n.d. URL https:\/\/www.bharatserums.com\/product\/emergency\/SVAS%20IP%20(Liquid)%20Pack%20Insert%20for%20Domestic.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib222","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bc010003g","article-title":"Prolonged in\u00a0vivo residence times of antibody fragments associated with albumin","volume":"12","author":"Smith","year":"2001","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib223","unstructured":"Product information. Snake Antivenin (Polyvalent) I.P. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_india-biologicale-snakeantiveninip_2011-07-28.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib224","unstructured":"Premium Serums. Snake Venom Antiserum (North Africa). [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product7.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib225","unstructured":"Premium Serums. Snake Venom Antiserum - Lyophilized. [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product1.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib226","unstructured":"Premium Serums. Snake Venom Antiserum (African - Ten). [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product6.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib227","unstructured":"Premium Serums. Snake Venom Antiserum (Central Africa). [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product3.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib228","unstructured":"Premium Serums. Snake Venom Antiserum I.P. [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product2.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib229","unstructured":"Premium Serums. Snake Venom Antiserum (Pan Africa). [WWW Document], n.d. URL http:\/\/www.premiumserums.com\/product5.html (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.biologicals.2011.11.006","article-title":"Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation","volume":"40","author":"Solano","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.03.004_bib231","unstructured":"Product information. Soro antibotropico (pentavalente) e anticrotalico. [WWW Document], n.d. URL http:\/\/www.anvisa.gov.br\/datavisa\/fila_bula\/frmVisualizarBula.asp?pNuTransacao=11751492016&pIdAnexo=3050338 (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib232","unstructured":"Product information. Soro Antibotropico (pentavalente) e antilaquetico. [WWW Document], n.d. URL http:\/\/www.funed.mg.gov.br\/wp-content\/uploads\/2015\/04\/BULFJ-0046-REV02_Profissional-de-Sa%C3%BAde.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib233","unstructured":"Product information. Soro Anticrot\u00e1lico. [WWW Document], n.d. URL http:\/\/www.funed.mg.gov.br\/wp-content\/uploads\/2015\/04\/BULFJ-0047-REV02_Profissional-de-Sa%C3%BAde_NOTIFICADAS.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib234","unstructured":"Product information. Soro Antielapidico (bivalente). [WWW Document], n.d. URL http:\/\/www.funed.mg.gov.br\/wp-content\/uploads\/2015\/04\/BULFJ-0048-REV02_Profissional-de-Sa%C3%BAde.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib235","unstructured":"Package leaflet: Soro antiescorpionico - Butantan. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_brasil-butantan-scorpionico_2011-07-05.pdf (accessed 7.15.16)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib236","unstructured":"Product information. Soro Antiescorpi\u00f4nico (FUNED). [WWW Document], n.d. URL http:\/\/www.anvisa.gov.br\/datavisa\/fila_bula\/frmVisualizarBula.asp?pNuTransacao=1233402015&pIdAnexo=2447866 (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib237","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.toxicon.2006.11.023","article-title":"Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a na\u00efve phage display library: preliminary findings for antivenom development","volume":"49","author":"Stewart","year":"2007","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib238","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1042\/bj3030163","article-title":"Characterization of monoclonal antibodies against Naja naja oxiana neurotoxin I","volume":"303","author":"Stiles","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.toxicon.2018.03.004_bib239","doi-asserted-by":"crossref","first-page":"e2326","DOI":"10.1371\/journal.pntd.0002326","article-title":"Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation","volume":"7","author":"Stone","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib240","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1074\/jbc.M709179200","article-title":"N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies","volume":"283","author":"Stork","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib241","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.toxicon.2012.06.003","article-title":"Recognition of Vipera ammodytes meridionalis neurotoxin vipoxin and its components using phage-displayed scFv and polyclonal antivenom sera","volume":"60","author":"Stoyanova","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib242","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","article-title":"DARPins: a new generation of protein therapeutics","volume":"13","author":"Stumpp","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.toxicon.2018.03.004_bib243","unstructured":"Suero antiescorpi\u00f3nico. Centro de Biotechnologia Facultad de Farmacia. [WWW Document], n.d. URL http:\/\/www.biotecfar.com.ve\/biotecfar\/pdf\/suero_antiescorpionico.pdf (accessed 4.25.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib244","unstructured":"Suero Antiofidico polivalente. Centro de Biotechnologia Facultad de Farmacia. [WWW Document], n.d. URL http:\/\/www.biotecfar.com.ve\/biotecfar\/pdf\/suero_antiofidico_polivalente.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.toxicon.2018.03.004_bib246","unstructured":"Taipan Antivenom - Curent Consumer Medicine information Nov 2017. [WWW Document], n.d. URL http:\/\/www.csl.com.au\/docs\/193\/38\/Taipan%20Antivenom%20-%20Curent%20Consumer%20Medicine%20information%20Nov%202017.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib247","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.bbagen.2006.04.008","article-title":"Expression of recombinant human antibody fragments capable of inhibiting the phospholipase and myotoxic activities of Bothrops jararacussu venom","volume":"1760","author":"Tamarozzi","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.toxicon.2018.03.004_bib248","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.toxicon.2003.10.010","article-title":"Snake venom metalloproteinases: structure\/function relationships studies using monoclonal antibodies","volume":"42","author":"Tanjoni","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib249","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.toxicon.2003.10.011","article-title":"Phylogenetic conservation of a snake venom metalloproteinase epitope recognized by a monoclonal antibody that neutralizes hemorrhagic activity","volume":"42","author":"Tanjoni","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/protein\/gzu007","article-title":"Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications","volume":"27","author":"Tiede","year":"2014","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"10.1016\/j.toxicon.2018.03.004_bib251","unstructured":"Tiger Snake Antivenom - Current Consumer Medicine Information Oct 2016. [WWW Document], n.d. URL http:\/\/www.csl.com.au\/docs\/950\/913\/Tiger%20Snake%20Antivenom%20-%20Current%20Consumer%20Medicine%20Information_Oct%202016.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib252","doi-asserted-by":"crossref","first-page":"14149","DOI":"10.1074\/jbc.M112.348912","article-title":"Diabody mixture providing full protection against experimental scorpion envenoming with crude Androctonus australis venom","volume":"287","author":"di Tommaso","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.toxicon.2018.03.004_bib253","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0014-5793(86)81024-9","article-title":"A\u00a0monoclonal antibody which recognized the functional site of snake neurotoxins and which neutralizes all short-chain variants","volume":"208","author":"Tr\u00e9meau","year":"1986","journal-title":"FEBS Lett."},{"issue":"73","key":"10.1016\/j.toxicon.2018.03.004_bib254","article-title":"Effect of culture medium, host strain and oxygen transfer on recombinant Fab antibody fragment yield and leakage to medium in shaken E.\u00a0coli cultures","volume":"12","author":"Ukkonen","year":"2013","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.toxicon.2018.03.004_bib255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/protein\/gzr061","article-title":"Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A","volume":"25","author":"Unverdorben","year":"2012","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.toxicon.2018.03.004_bib256","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jmb.2012.08.029","article-title":"Designed Armadillo repeat proteins: library generation, characterization and selection of peptide binders with high specificity","volume":"424","author":"Varadamsetty","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib257","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/bph.12106","article-title":"Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands","volume":"168","author":"Vauquelin","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib258","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.toxicon.2005.08.010","article-title":"Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers","volume":"46","author":"V\u00e1zquez","year":"2005","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.03.004_bib259","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.intimp.2010.08.018","article-title":"Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers","volume":"10","author":"V\u00e1zquez","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.intimp.2010.01.005","article-title":"Pharmacokinetics in rabbits and anti-sphingomyelinase D neutralizing power of Fab, F(ab\u2019)2, IgG and IgG(T) fragments from hyper immune equine plasma","volume":"10","author":"V\u00e1zquez","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib261","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pep.2011.03.005","article-title":"Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase","volume":"79","author":"Veggiani","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.toxicon.2018.03.004_bib262","unstructured":"Product information. Viper Venom Antitoxin. [WWW Document], n.d. URL http:\/\/biomed.com.pl\/plik\/4b702c5896772-antytoksyna_jadu_zmij_karta_charakterystyki_en.pdf (accessed 11.29.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib263","unstructured":"Product information. ViperaTAb. [WWW Document], n.d. URL http:\/\/www.toxinfo.org\/antivenoms\/resources\/antivenom_uk-micropharm-viperatab_2011-03-23.pdf (accessed 4.25.17)."},{"key":"10.1016\/j.toxicon.2018.03.004_bib264","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.toxicon.2018.03.004_bib265","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nbt.3040","article-title":"Biopharmaceutical benchmarks 2014","volume":"32","author":"Walsh","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib266","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxicon.2018.03.004_bib267","series-title":"Monoclonal Antibody Production","author":"Ward","year":"1999"},{"key":"10.1016\/j.toxicon.2018.03.004_bib268","series-title":"Handbook of Clinical Toxicology of Animal Venoms and Poisons","first-page":"493","article-title":"Clinical toxicology of snakebite in Asia","author":"Warrell","year":"1995"},{"key":"10.1016\/j.toxicon.2018.03.004_bib269","series-title":"Rabies and Envenomings: a Neglected Public Health Issue: Report of a Consultative Meeting","author":"Warrell","year":"2007"},{"key":"10.1016\/j.toxicon.2018.03.004_bib270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0167-7799(96)10062-7","article-title":"Effect of glycosylation on antibody function: implications for genetic engineering","volume":"15","author":"Wright","year":"1997","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib271","first-page":"21","article-title":"Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology Int","volume":"2","author":"Wu","year":"1996","journal-title":"J.\u00a0Immunol. Eng."},{"key":"10.1016\/j.toxicon.2018.03.004_bib272","first-page":"47","article-title":"Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging","volume":"4","author":"Wu","year":"1999","journal-title":"Tumor Target"},{"key":"10.1016\/j.toxicon.2018.03.004_bib273","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/nbt1026","article-title":"Production of recombinant protein therapeutics in cultivated mammalian cells","volume":"22","author":"Wurm","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib274","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270008316886","article-title":"Population pharmacokinetics of infliximab in patients with ankylosing spondylitis","volume":"48","author":"Xu","year":"2008","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.toxicon.2018.03.004_bib275","first-page":"1039","article-title":"Preparation and characterization of beta 1-bungarotoxin bispecific monoclonal antibody","volume":"47","author":"Yang","year":"1999","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.toxicon.2018.03.004_bib276","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.toxicon.2018.03.004_bib277","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1432-1033.1992.tb16635.x","article-title":"Amino acid sequence and immunological characterization with monoclonal antibodies of two toxins from the venom of the scorpion Centruroides noxius Hoffmann","volume":"204","author":"Zamudio","year":"1992","journal-title":"Eur. J. Biochem."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118301144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118301144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:15:09Z","timestamp":1751480109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010118301144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":277,"alternative-id":["S0041010118301144"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.03.004","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pros and cons of different therapeutic antibody formats for recombinant antivenom development","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}